Background: Adenomyosis is a common condition that is often associated with poor reproductive outcome. Repeated implantation failure in in vitro fertilization (IVF) cycles can result from impaired implantation caused by adenomyosis. The evidence regarding the role of long-term suppression (LTS) with gonadotropin-releasing hormone agonists (GNRHa) prior to embryo transfer (ET) in cases of adenomyosis is limited and conflicting.
Aim: The aim of this study was to assess the efficacy of long-term GNRHa therapy on livebirth rates in women with adenomyosis and infertility.
Design: The following case series includes 15 women with infertility and known adenomyosis undergoing in vitro fertilisation (IVF) that underwent at least three months downregulation with GNRHa prior to ET. Outcomes were compared to previous cycles performed without LTS.
Results: LTS with GNRHa was given in 16 cases (94.1%) prior to ET. In one case (5.9%) 6 months suppression was given. The majority of these patients had previous unsuccessful IVF cycles prior to LTS protocol with GnHRa. 17 embryo transfers (16 frozen, 1 fresh from donor) following LTS protocol resulted in 10 liveborn deliveries at term (58.8%) vs. a live birth rate of only 7.7% per ET without LTS (26 embryo transfers resulting in 2 live births; P<0.0001). Only three women who underwent long term GnRHa downregulation had no successful embryo transfers.
Conclusion: Our successful outcomes support the use of LTS with GnRHa to improve reproductive outcomes.
Corresponding author: Dr Catherine Schepisi email@example.com
Adenomyosis is a benign estrogen dependent disease whereby ectopic endometrial glands or stroma are found within the myometrium, surrounded by myometrial smooth muscle cell hyperplasia and hypertrophy [1-3]. It can be diffuse or focal depending on extent of uterine spread [4, 5]. Women with adenomyosis typically present with dysmenorrhea, heavy menstrual bleeding or infertility, however a large proportion can be asymptomatic . Therefore, true prevalence is unknown, with large variations between 5-70% cited within the literature [3, 6, 7]. Previously thought to be a disease associated with older multiparous women, delayed fertility and advancements in imaging techniques have led to an increased diagnosis in younger women of reproductive age being investigated for infertility . Adenomyosis has been associated with poor reproductive prognoses [9, 10]. Multiple factors have been implicated including impaired implantation and utero-tubal disruption [11, 12]. Of particular interest is the impact of poor endometrial receptivity on implantation, which has been suggested to be more significant than embryo quality . Increasing evidence is emerging to support the role of long-term GnRHa downregulation in improved reproductive outcomes, especially when used in conjunction with IVF or intracytoplasmic sperm injection [7, 14-16]. The following case series details successful pregnancy outcomes following GnRHa down regulation prior to embryo transfer (ET), further supporting the existing evidence and theorises its main mechanism of action is by improving endometrial receptivity.
This is a retrospective case series that includes 15 patients diagnosed with adenomyosis and treated with long acting GnRHa prior to their IVF treatment. These patients were chosen from a population of patients attending a private IVF clinic. All women included required an ultrasound diagnosis of adenomyosis. Patients were treated with at least 3 months of Goserelin Acetate Implant (Zoladex®) as part of the IVF protocol prior to ET. The study was reviewed by the Epworth Healthcare ethical review board and registered as a quality assurance study. Data was retrospectively collated from patient files and included patient demographics, previous obstetric history, prior fertility treatment and outcomes as well as significant past medical history. Data were analysed to assess the effect of long-term GnRHa downregulation on reproductive outcomes. Other factors impacting fertility were also recorded for each patient (See Table 1).
Data analysis was performed using SPSS Statistics, version 11. Descriptive characteristics of data are presented as median and interquartile range. Test of statistical significance for categorical variables was done using Pearson’s chi-square test and T-Test for non-categorical variables. Statistical significance was set at a p value <0.05.
received long acting GnRHa down regulation were reviewed. The average age of the patients was 37.5 years (range 28-48, SD 6.5). Most of the patients had concurrent diagnosis of endometriosis (13 patients, 86.7%) that was also treated prior to the commencement of the current long-acting suppression (LTS) protocol, none of the patients had surgery immediately prior to the commencement of the LTS protocol. All of the endometriosis surgeries that were performed occurred prior to cycles with regular ET without LTS. Diffuse adenomyosis was reported in 14 of the women (93.3%) while one patient had focal adenomyosis. All patients were diagnosed using ultrasound scans that were performed by a certified obstetrics and gynecology ultrasound specialists. Further data regarding patient characteristics can be found in Table 1.
Three months of long-term suppression with Zoladex was given in 16 cases (94.1%) prior to ET (Table 2). In one case (5.9%) 6 months suppression was given due to significant abnormal uterine bleeding. Frozen embryos were transferred in 16 (94.1%) patients after long term suppression (LTS) and a fresh embryo was transferred in one case (5.9%). Embryo transfers without LTS protocol included 15(57.7%) frozen embryos and 11 (42.3%) fresh embryos.
The majority of these patients had previous unsuccessful IVF cycles prior to LTS protocol with GnRHa down regulation. All patients had a single embryo transfer in all cycles. 17 embryo transfers (16 frozen, 1 fresh from donor) following LTS protocol resulted in 10 liveborn deliveries at term (58.8%) vs. a live birth rate of only 7.7% per ET without long term down regulation (26 embryo transfers resulting in 2 live births), this was statistically significant (P<0.0001). Only three women who underwent long term GnRHa downregulation had no successful embryo transfers. Total pregnancy rates were significantly better as well in the long-term suppression group (58.8% vs 19.2%, P=0.008 excluding chemical pregnancies, or 64.7% vs 26.9%, P=0.014 including chemical pregnancies).
Although most patients in this study had concurrent endometriosis, none of the LTS ET cycles were performed immediately following surgery for endometriosis. Furthermore, even though 9 patients underwent excision of endometriosis prior to other cycles, none of the patients had a live birth following the surgery (0%) while 6 of them (66.7%) had a live birth following LTS protocol. This superiority of LTS in cases of adenomyosis compared with endometriosis surgery was statistically significant (p=0.003).
The pathogenesis of adenomyosis is not completely understood. Adenomyosis is associated with a higher prevalence of recurrent pregnancy loss, failed assisted-reproductive treatment (ART) and poorer IVF reproductive outcomes [16-19]. Adenomyosis is suspected to impact fertility through a range of molecular mechanisms resulting in recurrent implantation failure (Figure 1). Adenomyosis related junctional zone disturbance causes dysperistalsis, impairing sperm transport and blastocyst implantation [12, 20, 21]. Hypoestrogenism, found in women with adenomyosis, perpetuates this dysperistalsis .
Impaired endometrial receptivity is also associated with implantation failure . Adenomyosis has been associated with reduced endometrial receptivity markers, such as integrin ß3 and leukaemia-inhibiting factor, HOXA10 and HOXA11, which play critical roles in implantation as well as endometrial growth, differentiation and decidualisation[24, 25]. Pinopodes are morphological markers of endometrial receptivity seen on the endometrial surface at the time of implantation . Decreased numbers and poorly formed pinopodes have been seen in human and mice studies with adenomyosis [25-27].
There however remains conflicting reviews in current literature regarding the impact of adenomyosis on infertility, with several authors concluding that cases with concurrent endometriosis confound and limit available evidence [16, 22, 28]. A 2014 meta-analysis found a 28% reduction in likelihood of clinical pregnancy in women with adenomyosis undergoing IVF or ICSI and suggests screening for adenomyosis prior to ART . A retrospective cohort study of 213 women showed a significantly decreased rate of viable clinical pregnancies in women with adenomyosis undergoing IVF with GnRH antagonist for ovarian stimulation . Furthermore, Dueholm’s review found an overall reduction in pregnancy rate with adenomyosis (RR 0.63) and an increased risk of miscarriage . In contrast, a case-control retrospective study of 49 women with adenomyosis having oocyte donation showed no significant differences in implantation rates . Benaglia’s  prospective cohort study also showed no significant difference in clinical or ongoing pregnancy rates in women with adenomyosis undergoing IVF. Similar findings have been found in other studies [32, 33].
Overall, the heterogeneity of studies investigating adenomyosis and infertility make it difficult to compare results. There are no high quality studies, with those published being limited by their retrospective nature, differing diagnostic criteria, small sample sizes, differing ages and concurrent endometriosis [7, 20, 34, 35]. There is also a lack of studies looking at the effect of adenomyosis on natural conception .
There are no current guidelines specific to the management of adenomyosis, especially for those seeking fertility assistance . Medical treatment is limited in patients that wish to conceive and hysterectomy is not a valid option for these patients. Growing desire for fertility preservation has seen an increase in cytoreductive surgeries performed and development of safer surgical techniques . Whilst surgical excision of adenomyosis improves symptoms and fertility outcomes they are not without risk, including uterine adhesions and pregnancy complications such as uterine rupture [37, 38].
It is thought that GnRHa improves fertility in women with adenomyosis through reduction in hyper estrogenic states both indirectly through to hypothalamic-pituitary axis and directly at the level of the tissues by normalising the endometrial over-expression of aromatase cytochrome P450 that occurs in adenomyosis . GnRHa has also been shown to have an antiproliferative and apoptotic effect on endometrial cells in vitro and Khan identified suppressed pathologic lesions in women with adenomyosis. GnRHa therapy may improve endometrial receptivity by reducing the extent of basal endometrium dislocation that occurs in adenomyosis . A retrospective cohort study by Bao et al also found an increase in endometrial receptivity markers following long-acting GnRHa protocol and significant increase in clinical pregnancy rates in women with decreased ovarian reserve.
Over the last decade, four retrospective cohort studies have evaluated the use of GnRHa downregulation on fertility and IVF outcomes in adenomyosis[41-44]. Niu  compared clinical pregnancy rates in the first IVF cycle post treatment with GnRHa and HRT versus HRT alone. They found that one month of GnRHa downregulation doubled implantation and ongoing clinical pregnancy rates. Small case series further support the benefit of GnRHa downregulation prior to IVF [45, 46]. However following 2-3 months of monthly goserelin, Park  found no statistical difference in clinical pregnancy rates. A small RCT found no significant difference in outcomes. Data regarding the effect of long term down regulation with GnRHa is limited .
We believe that adenomyosis can severely impair fertility and that our results further support this. Our cases were chosen for intervention following repeated failed IVF cycles, thought to be a result of their severe adenomyosis. Almost all of these patients had recurrent implantation failures prior to treatment with long term GnRHa downregulation. Our results show significant highly successful fertility outcomes post three months of GnRHa therapy prior to embryo transfer supporting its use in management of infertility. This differs from other evidence where successful cases with GnRHa downregulation were seen only following cytoreductive surgery [49-51]. Use of GnRHa therapy alone would likely be associated with less risks than in combination with surgical management, however whilst the women in our case series tolerated GnRHa therapy well (all successfully completing a minimum of three-months treatment), the side effects from a hypooestrogenic state may not be tolerated by all. Tolerance may be regime dependant and currently there remain large discrepancies in GnRHa downregulation regimes [41, 42, 44]. Our study has several limitations being retrospective in nature with a small sample size and high concurrent endometriosis rate. There was also selection bias as most patients had recurrent implantation failures in multiple cycles, this is also accentuated as the patients are their own controls. However, this significantly high success rate in a population that had very poor outcomes prior to this treatment is very promising. Acknowledging that outcomes will always be better after introduction of an intervention, we believe it supports further research to explore the impact of adenomyosis and GnRHa on implantation.
Our cases show promising results and support the use of long term GnRHa downregulation prior to frozen embryo transfer. The increased rate of pregnancy seen post GnRHa downregulation in this cohort may be attributed to increased endometrial receptivity promoted by GnRHa.
Furthermore, whilst we believe that GnRHa downregulation is a promising therapy for women with adenomyosis and infertility, further evidence is still required to assess its impact on pregnancy rates.
1. Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update. 1998;4:312-22.
2. García-Solares J, Donnez J, Donnez O, Dolmans M-M. Pathogenesis of uterine adenomyosis: invagination or metaplasia? Fertil Steril. 2018;109:371-9.
3. Hong SC, Khoo CK. An update on adenomyosis uteri. Gynecology and Minimally Invasive Therapy. 2016;5:106-8.
4. Benagiano G, Habiba M, Brosens I. The pathophysiology of uterine adenomyosis: an update. Fertil Steril. 2012;98:572-9.
5. Lazzeri L, Morosetti G, Centini G, Monti G, Zupi E, Piccione E, et al. A sonographic classification of adenomyosis: interobserver reproducibility in the evaluation of type and degree of the myometrial involvement. Fertil Steril. 2018;110:1154-61. e3.
6. Abbott JA. Adenomyosis and abnormal uterine bleeding (AUB-A)—pathogenesis, diagnosis, and management. Best practice & research Clinical obstetrics & gynaecology. 2017;40:68-81.
7. Soave I, Wenger J-M, Pluchino N, Marci R. Treatment options and reproductive outcome for adenomyosis-associated infertility. Curr Med Res Opin. 2018;34:839-49.
8. Naftalin J, Hoo W, Pateman K, Mavrelos D, Holland T, Jurkovic D. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod. 2012;27:3432-9.
9. Mochimaru A, Aoki S, Oba MS, Kurasawa K, Takahashi T, Hirahara F. Adverse pregnancy outcomes associated with adenomyosis with uterine enlargement. J Obstet Gynaecol Res. 2015;41:529-33.
10. Hashimoto A, Iriyama T, Sayama S, Nakayama T, Komatsu A, Miyauchi A, et al. Adenomyosis and adverse perinatal outcomes: increased risk of second trimester miscarriage, preeclampsia, and placental malposition. The Journal of Maternal-Fetal & Neonatal Medicine. 2018;31:364-9.
11. Kuijsters NPM, Methorst WG, Kortenhorst MSQ, Rabotti C, Mischi M, Schoot BC. Uterine peristalsis and fertility: current knowledge and future perspectives: a review and meta-analysis. Reprod Biomed Online. 2017;35:50-71.
12. Kissler S, Zangos S, Vogl T, Hamscho N, Gruenwald F, Kohl J, et al. Impaired utero-tubal sperm transport in adenomyosis and endometriosis—a cause for infertility. International Congress Series: Elsevier; 2004. p. 229-31.
13. Messaoudi S, Kasmi IE, Bourdiec A, Crespo K, Bissonnette L, Le Saint C, et al. 15 years of transcriptomic analysis on endometrial receptivity: what have we learnt? Fertility Research and Practice. 2019;5:9.
14. Dueholm M, Aagaard J. Adenomyosis and IVF/ICSI treatment: clinical considerations and recommendations. Taylor & Francis; 2018.
15. Vercellini P, Consonni D, Dridi D, Bracco B, Frattaruolo MP, Somigliana E. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod. 2014;29:964-77.
16. Vercellini P, Consonni D, Barbara G, Buggio L, Frattaruolo MP, Somigliana E. Adenomyosis and reproductive performance after surgery for rectovaginal and colorectal endometriosis: a systematic review and meta-analysis. Reprod Biomed Online. 2014;28:704-13.
17. Puente J, Fabris A, Patel J, Patel A, Cerrillo M, Requena A, et al. Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reprod Biol Endocrinol. 2016;14:1-9.
18. Salim R, Riris S, Saab W, Abramov B, Khadum I, Serhal P. Adenomyosis reduces pregnancy rates in infertile women undergoing IVF. Reprod Biomed Online. 2012;25:273-7.
19. Shimizu Y, Fukuda J, Kawamura K, Tanaka T. Retrospectively analysis of the fertility of adenomyosis and the outcome of adenomyosis complicated pregnancy in in vitro fertilization patients. Fertil Steril. 2002;77:S50.
20. Dueholm M. Uterine adenomyosis and infertility, review of reproductive outcome after in vitro fertilization and surgery. Acta Obstet Gynecol Scand. 2017;96:715-26.
21. Larsen SB, Lundorf E, Forman A, Dueholm M. Adenomyosis and junctional zone changes in patients with endometriosis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2011;157:206-11.
22. Yan L, Ding L, Tang R, Chen Z-J. Effect of adenomyosis on in vitro fertilization/intracytoplasmic sperm injection outcomes in infertile women: a retrospective cohort study. Gynecol Obstet Invest. 2014;77:14-8.
23. Neykova K, Tosto V, Giardina I, Tsibizova V, Vakrilov G. Endometrial receptivity and pregnancy outcome. The Journal of Maternal-Fetal & Neonatal Medicine. 2020:1-15.
24. Xiao Y, Sun X, Yang X, Zhang J, Xue Q, Cai B, et al. Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window. Fertil Steril. 2010;94:85-9.
25. Guo S, Li Z, Yan L, Sun Y, Feng Y. GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. Drug Des Devel Ther. 2018;12:1621.
26. Bao H, Qu Q, Guo Z, Li W, Zhao H. Long-Acting GnRH Agonist Improves IVF Outcomes of Young Patients with Diminished Ovarian Reserve by Increasing Endometrial Receptivity. 2020.
27. Zhou W, Li D, Ziwei Z, Pan Y, Jiang Y, Zhu C. GnRH-a induced changes in endometrial pinopodes. 2020.
28. Maheshwari A, Gurunath S, Fatima F, Bhattacharya S. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update. 2012;18:374-92.
29. Thalluri V, Tremellen K. Ultrasound diagnosed adenomyosis has a negative impact on successful implantation following GnRH antagonist IVF treatment. Hum Reprod. 2012;27:3487-92.
30. Vergara V, Garcia G, Meseguer M, Garrido N, Simon C, Pellicer A. The presence of uterine adenomyosis does not affect implantation in an oocyte donation program. Fertil Steril. 2008;90:S376.
31. Benaglia L, Cardellicchio L, Paffoni A, Leonardi M, Faulisi S, Somigliana E. Adenomyosis does not influence pregnancy rate in women undergoing IVF. Fertil Steril. 2013;100:S292.
32. O’Connor D, Bedaiwy M, Dunne C, Taylor B, Havelock J, Lawrence C, et al. Outcomes for in vitro fertilization in uterine adenomyosis: a retrospective cohort study. Fertil Steril. 2016;106:e333-e4.
33. Benaglia L, Cardellicchio L, Leonardi M, Faulisi S, Vercellini P, Paffoni A, et al. Asymptomatic adenomyosis and embryo implantation in IVF cycles. Reprod Biomed Online. 2014;29:606-11.
34. Kishi Y, Yabuta M. The benefit of adenomyomectomy on fertility outcomes in women with rectovaginal endometriosis with coexisting adenomyosis. Gynecology and minimally invasive therapy. 2017;6:20-4.
35. Mavrelos D, Holland TK, O’Donovan O, Khalil M, Ploumpidis G, Jurkovic D, et al. The impact of adenomyosis on the outcome of IVF–embryo transfer. Reprod Biomed Online. 2017;35:549-54.
36. Donnez J, Donnez O, Dolmans M-M. Introduction: Uterine adenomyosis, another enigmatic disease of our time. Fertil Steril. 2018;109:369-70.
37. Osada H. Uterine adenomyosis and adenomyoma: the surgical approach. Fertil Steril. 2018;109:406-17.
38. Harada T, Khine YM, Kaponis A, Nikellis T, Decavalas G, Taniguchi F. The impact of adenomyosis on women’s fertility. Obstet Gynecol Surv. 2016;71:557.
39. Ishihara H, Kitawaki J, Kado N, Koshiba H, Fushiki S, Honjo H. Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas. Fertil Steril. 2003;79:735-42.
40. Khan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Ishimaru T, et al. Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma. Hum Reprod. 2010;25:2878-90.
41. Niu Z, Chen Q, Sun Y, Feng Y. Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis. Gynecol Endocrinol. 2013;29:1026-30.
42. Al Jama FE. Management of adenomyosis in subfertile women and pregnancy outcome. Oman Med J. 2011;26:178.
43. Wang PH, Fuh JL, Chao HT, Liu WM, Cheng MH, Chao KC. Is the surgical approach beneficial to subfertile women with symptomatic extensive adenomyosis? J Obstet Gynaecol Res. 2009;35:495-502.
44. Park CW, Choi MH, Yang KM, Song IO. Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment. Clinical and experimental reproductive medicine. 2016;43:169.
45. Hirata JD, Moghissi KS, Ginsburg KA. Pregnancy after medical therapy of adenomyosis with a gonadotropin-releasing hormone agonist. Fertil Steril. 1993;59:444-5.
46. Huang F, Kung F, Chang S, Hsu T. Effects of short-course buserelin therapy on adenomyosis. A report of two cases. The Journal of reproductive medicine. 1999;44:741-4.
47. Davar R, Dashti S, Omidi M. Endometrial preparation using gonadotropin-releasing hormone agonist prior to frozen-thawed embryo transfer in women with repeated implantation failure: An RCT. International Journal of Reproductive BioMedicine (IJRM). 2020:319–26-–26.
48. Sallam HN, Garcia‐Velasco JA, Dias S, Arici A, Abou‐Setta AM. Long‐term pituitary down‐regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev. 2006.
49. Shiau C-S, Hsieh C-C, Chang M-Y, Hsieh C-L, Hsieh T-T. Conservative treatment of uterine adenomyosis in the infertile women with combined preoperative gonadotropin-releasing hormone agonist therapy and cytoreductive surgery. Fertil Steril. 2007;88:S221.
50. Wang P-H, Yang T-S, Lee W-L, Chao H-T, Chang S-P, Yuan C-C. Treatment of infertile women with adenomyosis with a conservative microsurgical technique and a gonadotropin-releasing hormone agonist. Fertil Steril. 2000;73:1061-2.
51. Wang C-J, Yuen L-T, Chang S-D, Lee C-L, Soong Y-K. Use of laparoscopic cytoreductive surgery to treat infertile women with localized adenomyosis. Fertil Steril. 2006;86:462. e5-. e8.